Daratumumab Therapy Improved Myeloma Survival Outcomes
The Phase 3 PERSEUS trial reported higher progression-free survival rates for patients receiving daratumumab-based treatment.
Updated on Sept. 26, 2026 in Cancer
Live Poll
Do you trust that new medical research is significantly improving long-term cancer survival outcomes?
Results from the Phase 3 PERSEUS trial demonstrate that adding daratumumab to standard therapy significantly increases progression-free survival for newly diagnosed multiple myeloma patients. Participants receiving the regimen showed an 81.1% progression-free survival rate at 72 months, compared to 56.1% in the control group.
Why it matters
This combination regimen aims to improve induction, consolidation, and maintenance outcomes for transplant-eligible patients. By achieving higher rates of minimal residual disease negativity, the treatment reduces the risk of disease progression or death by 65%.
The PERSEUS trial recorded a 70.4% sustained minimal residual disease-negativity rate in the daratumumab arm, significantly higher than the 36.2% rate in the control group. Overall survival at 72 months reached 85.9% for the treatment group versus 78.6% for controls.
The players
PERSEUS Trial
This large-scale clinical study evaluates the efficacy of daratumumab-based therapeutic regimens for individuals with newly diagnosed multiple myeloma.
Erasmus MC Cancer Institute
Located in Rotterdam, Netherlands, this research institution is a major center for oncological study and provided leadership for the PERSEUS trial.
The details
Patients in the treatment group received subcutaneous daratumumab co-formulated with recombinant human hyaluronidase PH20 alongside VRd therapy. The protocol allowed for the discontinuation of daratumumab for participants who achieved and maintained sustained minimal residual disease negativity.
Timeline
The clinical trial had a median follow-up duration of 81.3 months.
Progression-free survival rates were measured at the 72-month mark.
The Big Picture
This study marks a significant progression in the clinical protocols established by the PERSEUS trial for treating multiple myeloma. The findings validate the use of monoclonal antibodies in early-line treatment settings to improve long-term disease management.
This trial highlights a more effective treatment regimen for transplant-eligible myeloma patients that may eventually become a standard of care. Patients should consult their oncologists regarding how these results may influence their specific treatment plans and medication options.
The takeaway
The study demonstrates that daratumumab significantly enhances the depth of response and long-term survival for transplant-eligible myeloma patients. These findings support the use of intensive, targeted early-line interventions to delay disease progression.
Further reading
For more information on current treatment standards, visit the Cancer section.
More information
View full details regarding the study methodology on the PERSEUS trial clinical registry page.
Live Poll
Do you trust that new medical research is significantly improving long-term cancer survival outcomes?
